Meningococcal Vaccines Market Estimation, Dynamics, Regional Share, Trends, 2024

Posted by Naveen on January 10th, 2019

Meningococcal disease is a fatal disease caused by a bacteria called as Neisseria Meningitides which cause potential infection in the meninges, the thin layers of connective tissues which surrounds spinal cord and brain. Common symptoms are bacteraemia, pneumonia and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes and lethargy.

Changing aspects of meningococcal vaccines market

Factors which are playing important role in the growth of meningococcal vaccines are-

  • Increases incidence of meningococcal disease
  • Growing awareness about availability of its vaccines
  • Government based initiatives
  • Increased R & D investments by different players with introduction of advanced vaccines are leading the growth of meningococcal vaccines market.

However, vaccines cost, lack of awareness about the disease and stringent regulatory policies are huge restraints in the global meningococcal vaccines market.

Market summary:

With encouraging government initiatives, the global market for meningococcal diseases is growing at expedited rate. The meningococcal vaccine market has very limited numbers of market players and is expecting a lot of new entries in the near future. With increasing awareness about the disease and availability of vaccine, MenA joined hands with other vaccine programs in Africa to prevent around 123000 deaths in 2018.

Regional Analysis

In the global meningococcal vaccines market, North America holds the strongest position followed by Europe. Factors such as population surge, increased cases of meningococcal diseases accounts for account share. In Europe, Germany, UK and France hold the largest share due to great healthcare facilities and government bases initiatives. Asia Pacific is showing a substantial growth due to disposable income, different government immunization to eradicate meningococcal diseases.

Read more Insights at


Notable market development

TRUMENBA (meningococcal group B vaccine) from Pfizer received approval from US FDA in 2014 to prevent meningococcal vaccine.

Some of the key market players in the global meningococcal vaccines market are-

  • GlaxoSmithKline plc. (UK)
  • JN-International Medical Corporation (U.S.)
  • Novartis International AG (Switzerland)
  • Sanofi (France)
  • Pfizer, Inc. (U.S.)
  • Baxter International, Inc. (U.S.)

The global meningococcal vaccines market is divided into following categories-

By type

  • Meningococcal Conjugate Vaccines
  • Meningococcal Polysaccharide Vaccine
  • Serogroup B Meningococcal Vaccine

By end-users

  • Hospitals
  • Clinic
  • Others

By geographical regions

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • The Middle East & Africa

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact us

Kemp House,

152 – 160 City Road,

London EC1V 2NX


Toll Free (US):+1-866-598-1553

Website @

Like it? Share it!


About the Author

Joined: November 15th, 2018
Articles Posted: 16

More by this author